Validity of cerebrospinal fluid biomarkers as endpoints in early-phase clinical trials for Alzheimer's disease.

Journal of Alzheimer's disease : JAD

Volumn 18, Issue 1, 2009, Pages 89-102

  Zhou, Bin ^a   Teramukai, Satoshi ^b   Yoshimura, Kenichi ^b   Fukushima, Masanori ^b  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; BIOASSAY; CEREBROSPINAL FLUID; CLINICAL TRIAL; COMPARATIVE STUDY; HUMAN; META ANALYSIS; STANDARD; TIME; VALIDATION STUDY;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; HUMANS; TAU PROTEINS; TIME FACTORS;

EID: 70349159788     PISSN: None     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2009-1124     Document Type: Article

References (0)